Literature DB >> 4096901

Properties of adenoviral DNA bound to the nuclear matrix.

H C Smith, R Berezney, J M Brewster, D Rekosh.   

Abstract

The association of adenoviral DNA with the high salt (2 M NaCl) resistant nuclear fraction, termed the nuclear matrix, has been investigated in HeLa cells at different times after infection with adenovirus type 5. When nuclear matrices were prepared in the absence of exogenously added nucleases, Ad5 DNA was quantitively associated with the matrix throughout the infection period (0-24 h). Moreover, early in infection (0-10 h) Ad5 DNA was severalfold enriched in DNase I digested nuclear matrices (8-15% of total nuclear DNA) compared to the high salt soluble chromatin fraction (85-90% of total nuclear DNA). At later times after infection, progressively more Ad5 DNA appeared in the chromatin fraction until, at 24 h, the nuclear matrix was strikingly depleted in Ad5 DNA. A large proportion of the Ad5 DNA in nuclear matrices prepared early in infection, e.g., 4 h, was full length in size. At later times (12-24 h) most of the viral DNA was fragmented to a size equivalent to total matrix DNA (100-1000 base pairs). The apparent switch of the matrix-associated viral DNA from a relatively DNase I resistant to sensitive state was initiated approximately at the time when viral DNA replication began (12 h). Since no discrete portion of the Ad5 genome was significantly enriched at the sites of attachment to the nuclear matrix throughout the infection period, the switch in DNase I sensitivity is not mediated by a change in DNA sequence attachment to the matrix.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4096901     DOI: 10.1021/bi00326a022

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Anchorage of adenoviral RNAs to clusters of interchromatin granules.

Authors:  S Besse; F Puvion-Dutilleul
Journal:  Gene Expr       Date:  1995

2.  RNA metabolism in nuclei: adenovirus and heat shock alter intranuclear RNA compartmentalization.

Authors:  R M Denome; E A Werner; R J Patterson
Journal:  Nucleic Acids Res       Date:  1989-03-11       Impact factor: 16.971

3.  Ultrastructural and biochemical comparisons of nuclear matrices prepared by high salt or LIS extraction.

Authors:  H C Smith; R L Ochs; D Lin; A C Chinault
Journal:  Mol Cell Biochem       Date:  1987-09       Impact factor: 3.396

4.  Alterations in nuclear matrix structure after adenovirus infection.

Authors:  Z H Zhai; J A Nickerson; G Krochmalnic; S Penman
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

Review 5.  The nuclear matrix--its role in the spatial organization and replication of eukaryotic DNA.

Authors:  H M van der Velden; F Wanka
Journal:  Mol Biol Rep       Date:  1987       Impact factor: 2.316

6.  Simian virus 40 associates with nuclear superstructures at early times of infection.

Authors:  J B Watson; J D Gralla
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

7.  Nuclear subcompartmentalization of simian virus 40 large T antigen: evidence for in vivo regulation of biochemical activities.

Authors:  R Schirmbeck; W Deppert
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Compartmentalization of cellular and viral DNAs in adenovirus type 5 infection as revealed by ultrastructural in situ hybridization.

Authors:  S Besse; F Puvion-Dutilleul
Journal:  Chromosome Res       Date:  1994-03       Impact factor: 5.239

9.  Identifying a property of origins of DNA synthesis required to support plasmids stably in human cells.

Authors:  Chen-Yu Wang; Bill Sugden
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-08       Impact factor: 11.205

10.  The terminal regions of adenovirus and minute virus of mice DNAs are preferentially associated with the nuclear matrix in infected cells.

Authors:  J W Bodnar; P I Hanson; M Polvino-Bodnar; W Zempsky; D C Ward
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.